The Pharmacotherapy Research Center (PRC) is a collaborative hub for the School of Pharmacy and Pharmaceutical Sciences

Go To:

Main Menu

Research Operations & Training

Training opportunities

IInternational Programs

National Institute of Allergies and Infectious Diseases(NIAID)

National Institute of Mental Health (NIMH)

National Institute on Drug Abuse (NIDA)

Sponsored Programs

Core Analytical Laboratory

You do not have JavaScript enabled. Some portions of this website will not work properly without it. Please click here to find out how to enable JavaScript on your browser.

University at Buffalo, the State University of New York School of Pharmacy and Pharmaceutical Sciences

HPLC

Tipranavir

Antiretrovirals

Nevirapine and Abacavir

Sumitriptan

Delavirdine and its Metabolite

Efavirenz

Free Phenytoin

New assays in development:

darunavir assay, which will include atazanavir, efavirenz, lopinavir, saquinavir, and ritonavir
nevirapine, lamivudine and stavudine

Sumitriptan

Analyte	Lower Limit of Quantitation(ug/L)	Acceptable Anticoagulants	Required Plasma Volume	Excitation/Emission nM
Sumitriptan	0.005	Na Heparin	Minimal 0.6 mL	230/360

An isocratic reverse phase high performance liquid chromatography method measuring sumitriptan in heparinized, human plasma has been developed and validated at Pharmacotherapy Research Center's Core Analytical Laboratory. After the addition of internal standard, bufotenine, plasma specimens are prepared for chromatographic analysis via liquid-liquid extraction. The organic phase from the sample preparation is evaporated to dryness, reconstituted in mobile phase and injected into the reverse phase chromatographic system. Compounds are detected at a using a fluorescence detector using the excitation and emission settings of 230 nm and 360 nm, respectively. The lower limit of quantitation is 5 ng/mL.